Equity Overview
Price & Market Data
Price: $4.31
Daily Change: $0.00 / 0.00%
Daily Range: $2.69 - $4.55
Market Cap: $17,212,928
Daily Volume: 1,798,645
Performance Metrics
1 Week: 54.48%
1 Month: 71.71%
3 Months: 79.58%
6 Months: -30.93%
1 Year: -68.07%
YTD: 79.58%
Company Details
Employees: 17
Sector: Health technology
Industry: Medical specialties
Country: United States
Details
SeaStar Medical Holding Corporation, a commercial-stage medical device company, develops a proprietary platform therapy to reduce the consequences of hyperinflammation on vital organs in the United States. The company offers the selective cytopheretic device (SCD), which is a disease-modifying device that neutralizes over-active immune cells and stops the cytokine storm that yields destructive hyperinflammation; and QUELIMMUNE, an SCD therapy for pediatric patients with acute kidney injury (AKI) due to sepsis. It also develops NEUTRALIZE-AKI, an SCD therapy that is in clinical trials for adult patients with AKI; and other products in various therapeutic areas, including cardiorenal syndrome, hepatorenal syndrome, and myocardial stunning in end-stage renal disease. SeaStar Medical Holding Corporation was founded in 2007 and is headquartered in Denver, Colorado.